Lansen Pharmaceutical Holdings Limited provided earnings guidance for the twelve months ended 31 December 2022. For the period, the group expected to record a net profit attributable to equity owners of approximately USD 8.1 million, representing an increase of approximately USD 7.2 million (approximately 798% increase) compared to that of last year of approximately USD 0.9 million.
Lansen Pharmaceutical Holdings Limited
Equities
503
KYG5380M1033
Pharmaceuticals
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |